Teams published comprehensive multi‑omic analyses following a gene‑edited pig kidney transplanted into a brain‑dead human decedent and monitored for 61 days. Studies in Nature traced immune activation in the graft and identified antibody‑ and T‑cell–driven rejection signatures while also demonstrating reversal of rejection with an approved drug regimen. Researchers from the transplant team and collaborating institutions profiled human and pig gene expression, immune cell composition, and physiology across the two‑month window. The reports show actionable pathways and that clinically available immunomodulatory drugs can temper both humoral and cellular rejection in this setting, informing protocols for living‑patient trials. These datasets supply a day‑by‑day atlas of xenograft immune interactions and set guardrails for next‑generation clinical xenotransplant programs.